An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy who continued on extended use of vutrisiran, or switched from patisiran.

开始日期2024-12-03

申办/合作机构

Alnylam Pharmaceuticals, Inc.

NCT04153149

/ Active, not recruiting临床3期

HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

This study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in patients with ATTR amyloidosis with cardiomyopathy.

开始日期2019-11-26

申办/合作机构

Alnylam Pharmaceuticals, Inc.

NCT03759379

/ Active, not recruiting临床3期

HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

The purpose of this study is to evaluate the efficacy and safety of vutrisiran (ALN-TTRSC02) in participants with hereditary transthyretin amyloidosis (hATTR amyloidosis). Participants will receive vutrisiran subcutaneous (SC) injection once every 3 months (q3M) or the reference comparator patisiran intravenous (IV) injection once every 3 weeks (q3w) during the 18 month Treatment Period. This study will use the placebo arm of the APOLLO study (NCT01960348) as an external comparator for the primary and most other efficacy endpoints during the 18 Month Treatment Period. Following the 18 Month Treatment Period, all participants will be randomized to receive vutrisiran 50 mg SC injection once every 6 months (q6M) or vutrisiran 25 mg q3M in the Randomized Treatment Extension (RTE) Period. Upon implementation of Amendment 6, participants receiving vutrisiran SC 50 mg q6M will transition to vutrisiran SC 25 mg q3M at their next scheduled dosing.

开始日期2019-02-14

申办/合作机构

Alnylam Pharmaceuticals, Inc.

100 项与 Vutrisiran Sodium 相关的临床结果

登录后查看更多信息

100 项与 Vutrisiran Sodium 相关的转化医学

登录后查看更多信息

100 项与 Vutrisiran Sodium 相关的专利（医药）

登录后查看更多信息

项与 Vutrisiran Sodium 相关的文献（医药）

2025-12-01·Current Cardiology Reports

Transthyretin Cardiac Amyloidosis: Current and Emerging Therapies

Review

作者: Kesari, Aditya ; Shah, Keyur B ; Li, Pengyang ; Badrish, Narotham ; Patel, Aditi G M

Abstract:

Purpose of Review:

In this article, we describe current and newer TTR stabilizers, TTR silencers which include small interfering RNA agents (siRNA), antisense oligonucleotides (ASO) and CRISPR-Cas9 gene editing, and TTR depleters, which investigates the use of monoclonal antibodies to remove amyloid fibril deposits for patients with advanced disease.

Recent Findings:

Once thought to be a rare and fatal condition, increased recognition, improved non-invasive diagnostic tools, and the explosive development of novel therapies, has transformed the landscape of transthyretin amyloid cardiomyopathy (ATTR-CM). Advances in cardiac imaging with respect to echocardiography, cardiac magnetic resonance imaging (CMR), and radionuclide bone scintigraphy has increased the diagnosis of ATTR-CM over the last twenty years. Ongoing clinical trials are evaluating several novel therapies at several mechanistic targets in the transthyretin (TTR) amyloidogenesis cascade, including the recently published findings from the study of vutrisiran, a siRNA agent.

Summary:

Our review provides a comprehensive summary of current and emerging therapies for ATTR-CM. While these are promising, disease-modifying treatments, reaching vulnerable populations early in the disease course should be a focus for future studies and interventions.

2025-03-01·Molecular Therapy-Nucleic Acids

Development, opportunities, and challenges of siRNA nucleic acid drugs

Review

作者: Wang, Shaopeng ; Li, Chenxu ; Wang, Rong ; Pan, Yu ; Xiao, Bowen ; Guo, Tao ; Chen, Yong Q ; Zhi, Wenjun ; Zhai, Jiaqi ; Gu, Chensheng

Small interfering RNA (siRNA) drugs were first proposed in 1999. They have reached the market for administration to patients after more than 20 years of development. The US Food and Drug Administration has approved six siRNA drugs in recent years: patisiran, givosiran, lumasiran, vutrisiran, inclisiran, and nedosiran. siRNA drugs are based on the post-transcriptional gene regulation mechanism of RNA interference. These drugs have gained widespread attention for their effectiveness, low dosage, and low frequency of administration. Theoretically, siRNA drugs have great potential due to their ability to silence almost any target gene. However, drug delivery, especially the extrahepatic one, remains a major challenge. Currently, all approved drugs target the liver. The high blood flow, natural filtration function, and drug delivery methods of the liver overall ensure high efficacy and stability of the drugs themselves. This review summarizes the history of siRNA drug development and the mechanisms of action, with a focus on the drug targets, indications, and key clinical trial results to introduce the status of both marketed drugs and those currently in clinical trials. Additionally, this review provides a brief analysis of several key stages of the commercialization process of siRNA drugs.

2025-03-01·CURRENT OPINION IN CARDIOLOGY

New therapies to treat cardiac amyloidosis

Review

作者: Kamna, Daniel ; Nguyen, Olives ; Masri, Ahmad

Purpose of review:

Review advancements in therapies for transthyretin (ATTR-CM) and immunoglobulin light chain (AL-CM) cardiac amyloidosis.

Recent findings:

In ATTR-CM, tafamidis remains the cornerstone therapy, with Food and Drug Administration (FDA) approval for over 5 years. Acoramidis, another transthyretin stabilizer, has very recently been FDA-approved following positive results in the ATTRibute-CM trial. Vutrisiran, a transthyretin gene silencer, demonstrated efficacy in the HELIOS-B trial and awaits FDA review. Eplontersen's CARDIO-TTRansform trial, the largest ATTR-CM study to date, is expected to report by late 2025. Innovative approaches such as NTLA-2001 (a CRISPR-Cas9 therapy) and fibril depleters like ALXN2220 and coramitug are advancing in clinical trials. In AL-CM, daratumumab, cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) has established itself as the standard of care. Novel antiplasma cell therapies include CAR-T cells and bispecific antibodies (teclistimab) and fibril depleters. Birtamimab improved survival in advanced AL-CM during the VITAL trial and is under investigation in AFFIRM-AL. Anselamimab is in phase III CARES trials, whereas AT-02 undergoes early-phase testing for ATTR-CM and AL-CM.

Summary:

The therapeutic landscape for ATTR-CM and AL-CM is rapidly evolving, driven by novel therapies targeting diverse mechanisms. Ongoing clinical trials promise to further refine the standard of care and improve outcomes for patients with cardiac amyloidosis.

395

项与 Vutrisiran Sodium 相关的新闻（医药）

2025-03-26

·BioSpace

Trump’s Pharma Tariffs, Monarez for CDC, Novo’s New Obesity Play, More

President Donald Trump continues to warn of tariffs on the pharmaceutical industry; Susan Monarez replaces Dave Weldon as CDC director nominee; Novo Nordisk joins the triple-G race; Alnylam wins approval for Amvuttra in ATTR-CM; and Cassava Sciences ends development of simufilam in Alzheimer’s. > Listen on Spotify > Listen on Apple Products > Listen on Amazon Music > Listen on iHeart President Donald Trump doubled down on tariff threats targeting pharma, saying additional levies on pharmaceuticals will come “at some point,” per CNBC. Meanwhile, Johnson & Johnson became the latest big pharma to respond to Trump’s warning of potential tariffs if companies don’t reshore their manufacturing, announcing a massive $55 billion U.S. manufacturing and R&D investment. Not all companies are on board, however: AstraZeneca is looking eastward, pumping $2.5 billion into a new research facility in Beijing. Also on the policy front, Trump nominated acting CDC director Susan Monarez for the top job after pulling his first nominee, Dave Weldon , days before his senate hearing was expected to begin. If confirmed, Monarez would be the first CDC director since 1953 to not have a medical degree; she holds a Ph.D. in microbiology and immunology from the University of Wisconsin. In weight loss news, Novo Nordisk is paying China-based United Laboratories $200 million upfront to license a triple agonist of the GLP-1, GIP and glucagon receptors that could one day compete with Eli Lilly’s retatrutide. And BioSpace examines the next great challenge for GLP-1s: oral formulation manufacturing. Two more therapeutic spaces in focus last week are Duchenne muscular dystrophy and spinal muscular atrophy , where companies including Dyne Therapeutics, REGENXBIO and Novartis presented new data on their respective candidates. And the Duchenne community continued to react to news of the death of a patient taking Sarepta’s approved gene therapy Elevidys . In cardiovascular news, Alnylam won a much-anticipated approval for Amvuttra as the first RNAi silencer for transthyretin amyloid cardiomyopathy, setting up a three-way race with Pfizer’s tafamidis—marketed as Vyndaqel and Vyndama—and BridgeBio’s Attruby. Next up is Milestone Therapeutics’ CARDAMYST in paroxysmal supraventricular tachycardia, which has a PDUFA date of March 27. Finally, the saga of Cassava Sciences’ Alzheimer’s hopeful simufilam is over, as the company announced it has ended development of the controversial candidate.

高管变更基因疗法IPO上市批准

2025-03-25

·医药观澜

三个月一针，显著降低死亡率！潜在重磅疗法再获FDA批准

▎药明康德内容团队编辑编者按：日前，Alnylam公司的Amvuttra（vutrisiran）获得美国FDA批准，成为首款治疗伴有心肌病的转甲状腺素蛋白淀粉样变性（ATTR-CM）成人患者的siRNA疗法。值得关注的是，其采用的GalNAc偶联技术，是目前siRNA疗法的一大开发趋势——迄今FDA批准了6款siRNA疗法，除去尚在起步探索阶段的第一款，剩下5款均使用了GalNAc偶联技术，提升此类疗法的靶向性和稳定性。纵观目前的研发管线，也有超过350款候选siRNA疗法正在开发之中。为了更好地满足全球合作伙伴的研发需求，药明康德旗下专注于寡核苷酸和多肽及相关化学偶联药物的WuXi TIDES团队围绕GalNAc等分子，建立了定制合成、共价连接、以及一体化CMC的一站式服务平台，加速将合作伙伴的创新构想转化为现实，更好地造福全球病患。本文也将从Amvuttra的获批出发，分享GalNAc和新一代偶联寡核苷酸药物的广阔前景。只需三个月一针，显著降低患者死亡率日前，美国FDA批准Alnylam公司的siRNA疗法Amvuttra（vutrisiran）扩展适应症，治疗ATTR-CM成人患者。Vutrisiran是一款皮下给药的siRNA疗法，基于Alnylam的增强稳定化学（ESC）-GalNAc偶联递送平台设计，增加了效力和代谢稳定性。在3期临床试验中，它将患者的全因死亡率和复发性心血管事件的风险降低了28%（HR=0.72，95% CI：0.56-0.93，P=0.01）。新闻稿指出，vutrisiran是可同时治疗ATTR淀粉样变性患者的多发性神经病（polyneuropathy）和心肌病的首款FDA批准疗法。 GalNAc技术是推进siRNA疗法肝脏递送的突破性技术。它通过将与肝脏细胞表面高度表达的唾液酸糖蛋白受体（ASGPR）结合的GalNAc分子和siRNA分子偶联，促进siRNA分子被肝细胞吸收，增强siRNA分子的肝脏特异性递送。基于GalNAc偶联的递送技术问世以来，已经在siRNA药物开发领域得到广泛应用。FDA已经批准的6款siRNA疗法中，除了第一款疗法使用脂质纳米颗粒（LNP）作为递送系统，随后批准的5款疗法均使用了GalNAc偶联技术，足见这一递送系统的重要性。 ▲GalNAc技术作用机制简介（图片来源：Alnylam公司官网）随着GalNAc偶联技术的广泛应用和siRNA靶向递送系统的不断进展，越来越多的新锐公司致力于开发siRNA疗法。根据美国基因与细胞治疗学会（ASGCT）的统计，截至2024年底，siRNA研发管线中包含超过350款在研疗法，其中27%处于临床开发阶段。全面赋能，支持siRNA疗法早日进入临床这一新兴浪潮中，有一家生物技术公司在数年前找到WuXi TIDES，设想利用这一新分子疗法治疗心血管疾病，偶联GalNAc分子则是这款疗法的关键之一。但作为一类创新分子，GalNAc偶联siRNA的复杂性也带来了独特挑战——首先，这款疗法需要的GalNAc分子需要定制合成，并没有那么简单就能得到；其次，寡核苷酸部分的中间合成产物也并不稳定，难以满足后续的要求。尽管新药研发人员期待尽快在临床阶段检验这款疗法能否造福病患，但这些与分子复杂性相关的挑战，却成了开发道路上的“拦路虎”。为了实现合作伙伴的研发梦想，WuXi TIDES团队针对这款在研疗法开发的不同痛点，见招拆招。针对GalNAc片段需要定制合成的挑战，科学家们基于多年来在化学方面的积累，对合成路径进行了优化，在短时间内交付了高纯度的GalNAc片段，也大幅加速了项目的进程。而针对中间合成产物不稳定的痛点，科学家们也为合作伙伴开发了全新的工艺。利用曾斩获2022年诺贝尔化学奖的点击化学技术，WuXi TIDES团队简化了偶联分子的合成和纯化流程，带来了产品纯度和产率的提升——通过这一创新工艺，偶联分子的粗纯度从最初的18%提升到75%，产率也从最初的13%提高到62%，满足了客户的需求。最终，在14个月内，WuXi TIDES团队完成两款siRNA候选疗法的赋能工作，助力合作伙伴完成IND申请所需的准备工作，也让充满潜力的在研疗法距离患者更近一步。创新偶联技术造福更多患者 GalNAc偶联技术不但可以用于靶向递送siRNA，还可以助力其它寡核苷酸疗法的肝脏特异性递送。在2023年12月，阿斯利康（AstraZeneca）和Ionis Pharmaceuticals公司联合开发的反义寡核苷酸（ASO）疗法Wainua（eplontersen）获得FDA的批准，成为首款获批的GalNAc偶联ASO疗法。 GalNAc偶联技术解决了向肝脏特异性递送寡核苷酸药物的挑战。如今，研发人员正把目光投向肝脏以外的人体组织，通过将靶向其它组织的化合物、多肽、或抗体/抗体片段偶联在寡核苷酸药物上，促进寡核苷酸药物的肝外组织特异性递送，进一步扩展寡核苷酸药物治疗疾病的范围。比如，Avidity Biosciences和Dyne Therapeutics公司近日均公布了其偶联疗法在治疗杜氏肌营养不良症（DMD）方面的出色结果。这些疗法利用与肌肉组织表面受体特异性结合的抗体或抗体片段，促进具有治疗效果的寡核苷酸在肌肉组织中的表达。 ▲WuXi TIDES的“一站式”平台赋能各式偶联药物开发，治疗各种疾病 Alnylam公司创始首席执行官John Maraganore博士是siRNA疗法开发的先驱，去年他联合创建了致力于开发新一代siRNA疗法的City Therapeutics公司。在公司新闻稿中，他表示基于siRNA的治疗模式可能成为与单克隆抗体一样具有重大影响的治疗模式。而解锁基于这类药物的全部潜力，离不开siRNA的设计，以及将它们特异性靶向递送到更多组织类型方面的创新。GalNAc和其它创新偶联技术，正在打开让siRNA疗法治疗更多患者的大门。期待这些创新技术早日转化成为新药好药，为全球患者造福。参考资料： [1] Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM). Retrieved March 21, 2025, from https://www.businesswire.com/news/home/20250319752041/en/Alnylam-Announces-FDA-Approval-of-AMVUTTRA-vutrisiran-the-First-RNAi-Therapeutic-to-Reduce-Cardiovascular-Death-Hospitalizations-and-Urgent-Heart-Failure-Visits-in-Adults-with-ATTR-Amyloidosis-with-Cardiomyopathy-ATTR-CM [2] The ADME of siRNA GalNAc Conjugates. Retrieved March 21, 2025, from https://capella.alnylam.com/wp-content/uploads/2020/09/OTS-2020_MacLauchlin.pdf [3] The First FDA Approval for a GalNAc-conjugated ASO. Retrieved March 21, 2025, from https://www.oligotherapeutics.org/the-first-fda-approval-for-a-galnac-conjugated-aso/ [4] Gene, Cell, & RNA Therapy Landscape Report. Retrieved March 21, 2025, from https://www.asgct.org/global/documents/asgct-citeline-q4-2024-report.aspx [5] Fast-Track to Phase I: Two siRNA IND CMC Packages Completed in 14 Months. Retrieved March 21, 2025, from https://tides.wuxiapptec.com/wp-content/uploads/2024/07/Fast-Track-to-Phase-I-Two-siRNA-IND-CMC-Packages-Completed-in-14-Months-FINAL.pdf [6] Addressing oligonucleotide development challenges from a CRDMO’s perspective. Retrieved March 21, 2025, from https://tides.wuxiapptec.com/wp-content/uploads/2023/11/chemistry-today_panel-discussion_william-fang.pdf [7] 2024 WuXi AppTec Investor Day. Research Enabling Platforms Enhance CRDMO Model. Retrieved March 21, 2025, from https://officialsite-static.wuxiapptec.com/upload/2024_Wu_Xi_App_Tec_Investor_Day_Research_Enabling_Platforms_a656604c9a.pdf [8] 2024 WuXi AppTec Investor Day. WuXi Chemistry: A Global Leading CRDMO Platform. https://officialsite-static.wuxiapptec.com/upload/2024_Wu_Xi_App_Tec_Investor_Day_Wu_Xi_Chemistry_CRDMO_9996c65a2e.pdf [9] City Therapeutics Launches with $135 Million Series A Financing to Lead the Future of RNAi-based Medicine. Retrieved March 21, 2025, from, https://www.businesswire.com/news/home/20241008588238/en/City-Therapeutics-Launches-with-%24135-Million-Series-A-Financing-to-Lead-the-Future-of-RNAi-based-Medicine 本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权及其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

siRNA临床3期上市批准

2025-03-24

·drugs

FDA OKs Amvuttra To Treat Heart Conditions

MONDAY, March 24, 2025 -- The U.S. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra (vutrisiran), is made by Alnylam Pharmaceuticals and is used to treat transthyretin amyloid cardiomyopathy (ATTR-CM). ATTR-CM is a disease in which harmful proteins build up in the heart, making it harder to pump blood, according to the American Heart Association (AHA). In one study, Amvuttra helped lower the risk of death and heart problems by 28% over three years compared to a placebo. The drug is given as a shot every three months. “We hope this could become our flagship franchise. We’re going to help thousands more patients,” Alnylam CEO Yvonne Greenstreet said in an interview with STAT News . “It’s also a transformational moment for the company.” But the treatment comes at a steep price. Each dose costs about $119,000, or $476,000 per year. That’s more than double the cost of a similar drug from BridgeBio, and more expensive than Pfizer’s pills for the same condition. “There are many, many, many undiagnosed patients and substantial unmet need in this space. This market is very large, underdiagnosed, undertreated,” said Dr. Mani Foroohar , an analyst with the healthcare investment company Leerink. Still, the high cost may make it harder for patients -- especially folks on Medicare Advantage plans -- to get the drug. Private insurers may prefer cheaper options like pills from Pfizer or BridgeBio. Amvuttra works differently from those drugs. It uses RNA technology to stop the body from making the bad protein, while the other treatments work to stabilize the protein before it causes harm. In trials, BridgeBio’s treatment showed a 42% drop in deaths and heart hospital visits over 30 months. Amvuttra’s study showed a 28% drop over three years. But the trials were different, so it’s hard to compare the results directly. Amvuttra is already approved to treat a nerve-related form of ATTR. With this new approval, Alnylam hopes the drug will reach many more people. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

上市批准AHA会议临床研究临床结果

100 项与 Vutrisiran Sodium 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11916 D11917	-	-	DB16699

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
甲状腺素运载蛋白淀粉样变心肌病	美国	Alnylam Pharmaceuticals, Inc.	2025-03-20
转甲状腺素蛋白介导的淀粉样变性	澳大利亚	Medison Pharma Australia Pty Ltd.	2024-06-21
转甲状腺素运载蛋白淀粉样变性	美国	Alnylam Pharmaceuticals, Inc.	2022-06-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
斯塔加特病	临床2期	美国	Alnylam Pharmaceuticals, Inc.	2022-10-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04153149 (HELIOS-B, BusinessWire) 人工标引	临床3期	甲状腺素运载蛋白淀粉样变心肌病 N-terminal pro-B-type Natriuretic peptide \| Cardiac Troponin I	655	Vutrisiran 25mg	憲製醖夢鏇網衊衊醖鏇(繭獵網鹹願簾積壓襯壓) = 繭艱糧醖齋製蓋網鑰醖窪鏇築鑰膚壓餘艱夢醖 (獵鏇夢選範選鬱鏇餘窪 ) 更多	积极	2024-09-29
NCT04153149 (HELIOS-B, Pubmed \| N Engl J Med) 人工标引	临床3期	甲状腺素运载蛋白淀粉样变心肌病	655	Vutrisiran 25 mg	鑰艱簾網選網齋廠醖鏇(鹽鑰膚構鹽壓製獵遞鏇): HR = 0.72 (95% CI, 0.56 ~ 0.93), P-Value = 0.01 更多	积极	2024-08-30
				Placebo
NCT04153149 (HELIOS-B, Company_Website) 人工标引	临床3期	甲状腺素运载蛋白淀粉样变心肌病	655	Vutrisiran (overall population)	壓鬱製夢壓衊構鹹製選(淵憲醖廠鹹繭夢糧憲膚) = Rates of adverse events (AEs), serious AEs and AEs leading to study drug discontinuation were similar between the vutrisiran and placebo arms. No AEs were seen ≥3% more frequently in the vutrisiran arm compared to the placebo arm. 積醖艱鏇衊廠遞壓簾齋 (糧鑰餘遞廠願遞齋繭齋 )	积极	2024-06-24
				Vutrisiran (not receiving tafamidis at baseline)
NCT03759379 (HELIOS-A, Pubmed)	临床3期	家族性淀粉样神经病	164	Vutrisiran	簾鹹願願膚繭餘鹹窪齋(積襯範願鹹範壓選醖淵) = 餘繭廠壓襯憲餘壓糧蓋壓範繭淵齋獵鑰艱觸築 (鑰鹹構憲鏇齋衊觸製襯 )	-	2023-07-31
NCT01960348 \| NCT03759379 (APOLLO, ANA2022)	临床3期	多发性神经病 \| 淀粉样变性 NfL	-	Patisiran	鏇齋壓觸艱積襯蓋積觸(壓襯餘製築壓選廠鬱鹹) = 遞艱顧齋鹽壓簾鹽鹽夢鬱窪齋醖鬱選選製淵壓 (淵鑰築壓壓範襯糧構積 )	积极	2022-09-14
				Vutrisiran	鏇齋壓觸艱積襯蓋積觸(壓襯餘製築壓選廠鬱鹹) = 遞製積網醖獵廠繭選繭鬱窪齋醖鬱選選製淵壓 (淵鑰築壓壓範襯糧構積 )
NCT03759379 (HELIOS-A, Corporate Publications) 人工标引	临床3期	心肌疾病	199	vutrisiran	築鏇鑰鏇壓膚鑰壓壓醖(壓淵顧簾艱選膚衊鹽簾) = 觸夢積夢顧衊膚網鑰膚鑰鑰選夢憲觸餘鑰醖鹹 (壓壓衊鏇憲繭鹹鹹積餘 )	积极	2022-05-23
				Placebo	築鏇鑰鏇壓膚鑰壓壓醖(壓淵顧簾艱選膚衊鹽簾) = 鑰選網觸壓獵獵鹽襯選鑰鑰選夢憲觸餘鑰醖鹹 (壓壓衊鏇憲繭鹹鹹積餘 )
NCT03759379 (HELIOS-A, Corporate Publications) 人工标引	临床3期	淀粉样神经病	199	Vutrisiran	餘齋顧鬱鹹鹹積遞憲繭(糧夢窪鏇膚顧蓋築齋構) = 觸鬱選鹹觸糧壓鏇艱觸廠顧繭選築衊願糧繭廠 (夢構積齋製齋廠鏇鏇選 ) 更多	积极	2022-01-21
				Placebo	餘齋顧鬱鹹鹹積遞憲繭(糧夢窪鏇膚顧蓋築齋構) = 憲壓憲繭齋鹽選憲糧廠廠顧繭選築衊願糧繭廠 (夢構積齋製齋廠鏇鏇選 ) 更多